| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 12/18/2001 | CA2202484C Use of indole derivatives for the treatment of various diseases |
| 12/18/2001 | CA2178161C Indole derivatives |
| 12/13/2001 | WO2001094952A2 Methods and compositions for modulating oxidized ldl transport |
| 12/13/2001 | WO2001094636A2 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | WO2001094627A2 Assay techniques based on growth stage dependent expression in c. elegans |
| 12/13/2001 | WO2001094616A1 Protein markers for pharmaceuticals and related toxicity |
| 12/13/2001 | WO2001094605A2 Recombinant aav vectors for gene therapy of obesity |
| 12/13/2001 | WO2001094586A2 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 12/13/2001 | WO2001094582A1 Novel g protein-coupled receptor protein and dna thereof |
| 12/13/2001 | WO2001094581A1 Tumour suppressor and uses thereof |
| 12/13/2001 | WO2001094420A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | WO2001094415A2 Nuclear hormone receptor |
| 12/13/2001 | WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | WO2001094410A1 Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094368A1 2-aminocarbonyl-9h-purine derivatives |
| 12/13/2001 | WO2001094367A1 Malto-oligosaccharide derivatives and use thereof |
| 12/13/2001 | WO2001094351A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | WO2001094344A1 Thiazolidinedione salt for treatment of diabetes mellitus |
| 12/13/2001 | WO2001094343A1 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical |
| 12/13/2001 | WO2001094325A1 2-aminothiazoline derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001094321A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
| 12/13/2001 | WO2001094312A2 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 12/13/2001 | WO2001094307A1 Propanolaminotetralines, preparation thereof and compositions containing same |
| 12/13/2001 | WO2001094300A1 Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
| 12/13/2001 | WO2001094295A1 Substituted stilbenes as glucose uptake enhancers |
| 12/13/2001 | WO2001094293A2 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | WO2001093911A2 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | WO2001093886A1 Method of obtaining a tea pigment from tea leaves |
| 12/13/2001 | WO2001093885A1 Therapeutic agents - ii |
| 12/13/2001 | WO2001093884A1 Therapeutic agents - i |
| 12/13/2001 | WO2001093883A1 Therapeutic agents - iii |
| 12/13/2001 | WO2001093879A1 Biologically active agents and drugs |
| 12/13/2001 | WO2001093867A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001093860A1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| 12/13/2001 | WO2001093845A2 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | WO2001093836A2 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | WO2001093833A2 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 12/13/2001 | WO2001093669A2 Compound screens relating to insulin deficiency or insulin resistance |
| 12/13/2001 | WO2001044200A3 Selective neurokinin antagonists |
| 12/13/2001 | WO2001041701A3 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 12/13/2001 | WO2001040243A3 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives |
| 12/13/2001 | WO2001037820A3 Ionizable indolinone derivatives and their use as ptk ligands |
| 12/13/2001 | WO2000044888A3 Dimethylarginine dimethylaminohydrolases |
| 12/13/2001 | WO2000015845A9 T-type calcium channel |
| 12/13/2001 | US20010051646 Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| 12/13/2001 | US20010051636 Combination treatment for inhibiting bone loss |
| 12/13/2001 | US20010051626 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 12/13/2001 | US20010051623 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic |
| 12/13/2001 | US20010051619 E.g., ethyl 3-(4-(2-(3-oxo-2H-1,4-benzoxazin-4-yl)ethoxy)-phenyl-2-ethoxypropenoate where 1,4-benzothiazine or quinoxaline can be substituted for the benzoxazine ring; anticholesterol, diabetic agents; obesity; hyperlimpidemia |
| 12/13/2001 | US20010051601 Use of growth hormone in low dose |
| 12/13/2001 | US20010051595 Injection into blood |
| 12/13/2001 | CA2810249A1 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2413906A1 Carboxyalkylether-acat inhibitor combinations |
| 12/13/2001 | CA2412436A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2412377A1 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | CA2412326A1 Stabilized hmg-coa reductase inhibitor pharmaceutical compositions |
| 12/13/2001 | CA2411730A1 Tumour suppressor and uses thereof |
| 12/13/2001 | CA2411596A1 Therapeutic agents - ii |
| 12/13/2001 | CA2411542A1 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | CA2411473A1 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | CA2411340A1 Substituted stilbenes as glucose uptake enhancers |
| 12/13/2001 | CA2411065A1 Thiazolidinedione salt for treatment of diabetes mellitus |
| 12/13/2001 | CA2411064A1 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical |
| 12/13/2001 | CA2411062A1 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | CA2410512A1 Recombinant aav vectors for gene therapy of obesity |
| 12/13/2001 | CA2410509A1 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 12/13/2001 | CA2410188A1 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 12/13/2001 | CA2410158A1 Protein markers for pharmaceuticals and related toxicity |
| 12/13/2001 | CA2409392A1 Intracellular signaling proteins |
| 12/13/2001 | CA2409268A1 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | CA2409015A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | CA2408748A1 Nuclear hormone receptor |
| 12/13/2001 | CA2408611A1 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 12/13/2001 | CA2407164A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
| 12/13/2001 | CA2381249A1 Methods and compositions for modulating oxidized ldl transport |
| 12/12/2001 | EP1162458A1 Methods and compositions for modulating oxidized LDL transport |
| 12/12/2001 | EP1162207A1 Amylin agonist peptides and uses therefor |
| 12/12/2001 | EP1161954A1 Treatment of T cell mediated autoimmune disorders |
| 12/12/2001 | EP1161946A2 Soluble analogs of probucol |
| 12/12/2001 | EP1161687A1 Grb14 and the insulin receptor and screening of novel medicines |
| 12/12/2001 | EP1161549A2 Retrovirus producing cells utilizing a high multiplicity of transduction |
| 12/12/2001 | EP1161452A2 Covalently bridged insulin dimers |
| 12/12/2001 | EP1161448A1 49 human secreted proteins |
| 12/12/2001 | EP1161442A2 Exocytosis pathway proteins and methods of use |
| 12/12/2001 | EP1161434A1 Pyridopyranoazepine derivatives, preparation and therapeutic use |
| 12/12/2001 | EP1161433A1 Tyrosine kinase inhibitors |
| 12/12/2001 | EP1161429A2 Heterocyclic compounds as adenosine deaminase inhibitors |
| 12/12/2001 | EP1161422A1 Amine derivatives as protease inhibitors |
| 12/12/2001 | EP1161421A1 Inhibitors of protein tyrosine phosphatase |
| 12/12/2001 | EP1161419A1 Spirocyclic ketones and their use as tachykinin antagonists |
| 12/12/2001 | EP1161415A2 N-cyanomethylamides as protease inhibitors |
| 12/12/2001 | EP1161412A1 Nuclear receptor arylating compounds |
| 12/12/2001 | EP1161280A1 Use of an integrin antagonist and a chemotherapeutic agent in the treatment of neoplasia |
| 12/12/2001 | EP1161242A1 Composition and method for treating diabetes |
| 12/12/2001 | EP1161236A1 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors |
| 12/12/2001 | EP1161235A1 Combinations for the treatment of diseases involving angiogenesis |
| 12/12/2001 | EP1161233A2 Lxr modulators |
| 12/12/2001 | EP1161157A1 Food complement and method for cosmetic treatment based on a grape extract rich in polyphenols |
| 12/12/2001 | EP0785787B1 Use of 1,5-benzodiazepine derivatives for the control of gastric emptying in patients with non-insulin dependent diabetes mellitus |